Please assess the completion status of the following clinical trial:

Trial Title: Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years, eligible for surgery~2. Bethesda VI fine needle aspiration (FNA) thyroid or FNA proven PTC metastasis (primary or recurrence).~3. Scheduled to undergo central and/or lateral lymph node dissection with or without thyroidectomy as discussed in the Multi-Disciplinary Thyroid Board.~4. WHO performance score of 0-2.~5. Written informed consent.~6. Mentally competent person who is able and willing to comply with study procedures.~7. For female subjects who are of childbearing potential are premenopausal with intact reproductive organs or are less than two years post-menopausal:~   * A negative serum pregnancy test prior to receiving the tracer~  * Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.~Exclusion Criteria:~1. Pregnancy or breast feeding~2. Advanced stage thyroid cancer not suitable for surgical resection~3. Medical or psychiatric conditions that compromise the patient's ability to give informed consent~4. Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last three months prior to the start of the treatment~5. The subject has been included previously in this study or has been injected with another investigational medicinal product within the past six months~6. History of myocardial infarction (MI), TIA, CVA, pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment~7. Any significant change in their regular prescription or non-prescription medication between 14 days and 1 day prior to IMP administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EMI-137 0.09mg/kg administration (Type: EXPERIMENTAL): Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed.
- EMI-137 0.13mg/kg administration (Type: EXPERIMENTAL): Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed.
- EMI-137 0.18mg/kg administration (Type: EXPERIMENTAL): Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed.
- EMI-137 0.045mg/kg administration (Type: EXPERIMENTAL): If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).